NEWS

December 2010 Online chat and support group MPD-Chat has listed all abstracts presented at the recent American Society of Hematology meeting that are relevant to MPD/MPN. Take a look at the abstract as well as the discussion boards. Thanks to MPD Chat for compiling this list!

December 2010 Data from SBio’s ongoing clinical trial for their JAK2 Inhibitor SB1518 was reported at the recent annual meeting of the American Society of Hematology. Dr. Srdan Verstovsek reported that thus far 57% of patients enrolled had experience reduction in spleen as well as reduction in constitutional symptoms of myelofibrosis. The drug was reported… Read More »SBIO DRUG SHOWS PROMISE FOR SYMPTOM AND SPLEEN REDUCTION FOR MYELOFIBROSIS PATIENTS

December 2010 Incyte Corp. is currently working on phase II clinical trials for their JAK Inhibitor INCB18424. These trials are testing safety and efficacy of this drug, meant to relieve constitutional symptoms in ET and PV patients. Results were reported at the American Society of Hematology’s annual meeting. Click here for more information

December 2010 Drs. Ayalew Tefferi and Animesh Pardanani presented data at ASH on the benefits of two drugs currently in clinical trials: TG101348 and CYT387. TG101348 is currently being tested in myelofibrosis patients and has been shown to reduce constitutional symptoms as well as reduction in spleen size and JAK burden in many of the… Read More »MPD DOCTORS DISCUSS BENEFITS OF 2 JAK2 INHIBITORS

October 2010 SBio, based in Singapore, is working on a JAK2 Inhibitor for Myelofibrosis patients, SB1518. They have just been granted orphan drug designation from the European Commission. The European Commission is the executive body of the European Union, and has an orphan drug incentive program similar to the U.S. This development potentially expands the… Read More »SBIO GRANTED ORPHAN DESIGNATION FOR MYELOFIBROSIS DRUG

October 2010 The Indian Journal of Medical Research recently published an article reporting the prevalence of the JAK2 mutation among polycythemia vera, essential thrombocythemia and myelofibrosis patients at a clinic in northern India. The JAK2 mutation, a gene marker for the Myeloproliferative disorders, was discovered in 2005. To read the full article click here.

The September 2010 issue of Blood included an article on a new model for estimating risk of blood clot for a variety of cancer patients. Patients with the hematological malignancies lymphoma and multiple myeloma were included in the study along with hard tumor patients to develop a model by which doctors could better predict risk.… Read More »ASH PRESS RELEASE ON BLOOD CLOT RISK PREDICTION MODEL

September 2010 The FDA has approved a special protocol for Incyte’s clinical trial for Polycythemia Vera patients. Their RESPONSE (Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care) is expected to enroll approximately… Read More »INCYTE APPROVED BY FDA FOR SPECIAL PV PROTOCOL

TargeGen, producer of JAK2 inhibitor TG101348, was purchased on June 30 2010 by French pharmaceutical company Sanofi-Aventis. Sanofi-Aventis hopes to continue to develop drugs targeted at hematological malignancies. Clinical trials for TG101348 have completed enrollment. For the full press release click here.

The MPD Foundation is pleased to announce a Call for Proposals for its 2011 Challenge Grant Program. Worthy projects will advance the understanding of mechanisms of action in the MPD’s and/or contribute to accelerating the discovery and development of new treatments for MPD patients. The MPD Foundation is a private not-for-profit advocacy organization seeking to… Read More »ANNOUNCING CHALLENGE GRANT 2011